RXDX-105: Interim Phase I data

Interim data from 11 evaluable patients with advanced or metastatic solid tumors with RET or BRAF alterations in an

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE